Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 5, pp 637–642

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

Authors

    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Laura Catena
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Giuseppe Procopio
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Sara De Dosso
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Ettore Bichisao
    • I.T.M.O. Group
  • Leonardo Ferrari
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Antonia Martinetti
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Marco Platania
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Elena Verzoni
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Barbara Formisano
    • S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei Tumori
  • Roberto Bajetta
    • Pharmacology UnitIstituto Nazionale per lo Studio e la Cura dei Tumori
Original Article

DOI: 10.1007/s00280-006-0306-6

Cite this article as:
Bajetta, E., Catena, L., Procopio, G. et al. Cancer Chemother Pharmacol (2007) 59: 637. doi:10.1007/s00280-006-0306-6

Abstract

Purpose

The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours’ (NETs) treatment.

Methods

Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts).

Results

In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively.

Conclusions

The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues.

Keywords

CapecitabineChemotherapyNeuroendocrine tumoursOxaliplatinXELOX

Copyright information

© Springer-Verlag 2006